Beam Therapeutics

BEAM

Market cap $3.59B

Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.

Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.

Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302.

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026    Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway.

Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P.

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?